DEXCOM INC
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 9B. Other Information
Trading Plans
During the three months ended December 31, 2025, the following Section 16 officers and directors adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense of Rule 10b5-1(c):
| Name | Title | Action | Action Date | Aggregate Number of Shares to be Sold | Expiration Date(1) |
|---|---|---|---|---|---|
| Michael J. Brown | Executive Vice President, Chief Legal Officer | Adoption | 11/26/2025 | 20,400 | 2/26/2027 |
| Jacob S. Leach | President, Chief Executive Officer, and Director | Termination | 11/7/2025 | 102,732(2) | 3/12/2026 |
| (1) Each trading arrangement permitted or permits transactions through and including the date listed in the table. | |||||
| (2) As of the date of termination, no shares of common stock had been sold under the plan. | |||||
Each of the Rule 10b5-1 trading arrangements disclosed in the above table was made in accordance with ourinsider trading policy. Transactions made pursuant to such trading arrangements will be disclosed publicly in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations.
No Section 16 officers or directors adopted, modified, orterminated a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) during the three months ended December 31, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.